Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of MDG1011-treated subjects
2018-000717-20Phase 2Completed
- Sponsor
- Medigene AG
- Start
- Jul 2019
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of MDG1011 in myeloid diseases, lymphoid neoplasm, Malignant lymphoid neoplasm and 1 more, sponsored by Medigene AG. Primary endpoint: Persisting or delayed treatment-related adverse events. Started Jul 2019; status: completed.
02
Drugs
MDG1011
03
Conditions
myeloid diseaseslymphoid neoplasmMalignant lymphoid neoplasmcancer
Beyond the preview
Go deeper on 2018-000717-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000717-20.